GlassScriptPhysician profile
Kevin Coy
NPI 1336673235
$6,488.83
in general payments reported to CMS, 2019-2025
19 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $1,015 · 2023: $2,763 · 2024: $2,168 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Travel and Lodging: $1,506 · Grant: $1,063 · Education: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.70 |
| Travel and Lodging | $1,506.38 |
| Grant | $1,063.30 |
| Education | $567.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,738.89 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $1,409.86 | 2022-2025 | Cobalt Dr Mri Surescan, Corevalve Evolut R, Onyx Frontier |
| Boston Scientific Corporation | $1,063.30 | 2024 | |
| Abbott Laboratories | $669.41 | 2023-2024 | Ensite, Perclose Proglide, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $645.14 | 2021-2025 | Lifevest |
| Terumo Medical Corporation | $251.99 | 2022 | |
| Abiomed | $143.69 | 2024 | Impella |
| Amgen INC. | $111.89 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $78.18 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.12 | 2024-2025 | Jardiance |
| Cardiva Medical, INC. | $53.70 | 2025 | Optowire |
| Biotronik INC. | $46.85 | 2023 | Orsiro Mission |
| Astrazeneca Pharmaceuticals LP | $43.46 | 2023-2025 | Wainua, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $38.97 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $38.04 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $26.34 | 2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $26.07 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $24.05 | 2024 | |
| Bridgebio Pharma, INC. | $19.88 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Coy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.